BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olson KM, Traynor JR, Alt A. Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators. Front Chem 2021;9:671483. [PMID: 34692635 DOI: 10.3389/fchem.2021.671483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Olson KM, Campbell A, Alt A, Traynor JR. Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.1c00256] [Reference Citation Analysis]
2 Casadó-Anguera V, Casadó V. Unmasking allosteric binding sites: Novel targets for GPCR drug discovery. Expert Opin Drug Discov 2022. [PMID: 35649692 DOI: 10.1080/17460441.2022.2085684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Combarnous Y, Nguyen TMD. Membrane Hormone Receptors and Their Signaling Pathways as Targets for Endocrine Disruptors. JoX 2022;12:64-73. [DOI: 10.3390/jox12020007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Root-bernstein R. Biased, Bitopic, Opioid–Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction. Pharmaceuticals 2022;15:214. [DOI: 10.3390/ph15020214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]